Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Melanoma | Research

The podoplanin-CLEC-2 interaction promotes platelet-mediated melanoma pulmonary metastasis

Authors: Minjia Sheng, Ran Sun, Jianxin Fu, Gao Lu

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Background

Podoplanin (PDPN) expressed on tumour cells interacts with platelet C-type lectin-like receptor 2 (CLEC-2). This study aimed to investigate the role of the PDPN-platelet CLEC-2 interaction in melanoma pulmonary metastasis.

Methods

Murine melanoma B16-F0 cells, which have two populations that express podoplanin, were sorted by FACS with anti-podoplanin staining to obtain purified PDPN + and PDPN- B16-F0 cells. C57BL/6J mice transplanted with CLEC-2-deficient bone marrow cells were used for in vivo experiments.

Results

The in vivo data showed that the number of metastatic lung nodules in WT mice injected with PDPN + cells was significantly higher than that in WT mice injected with PDPN- cells and in WT or CLEC-2 KO mice injected with PDPN- cells. In addition, our results revealed that the platelet Syk-dependent signalling pathway contributed to platelet aggregation and melanoma metastasis.

Conclusions

Our study indicates that the PDPN-CLEC-2 interaction promotes experimental pulmonary metastasis in a mouse melanoma model. Tumour cell-induced platelet aggregation mediated by the interaction between PDPN and CLEC-2 is a key factor in melanoma pulmonary metastasis.
Appendix
Available only for authorised users
Literature
1.
2.
Maitra A. Molecular envoys pave the way for pancreatic cancer to invade the liver. Nature. 2019;567(7747):181–2.CrossRefPubMed
3.
4.
Strasenburg W, Jóźwicki J, Durślewicz J, Kuffel B, Kulczyk MP, Kowalewski A, Grzanka D, Drewa T, Adamowicz J. Tumor Cell-Induced platelet aggregation as an emerging therapeutic target for Cancer Therapy. Front Oncol. 2022;12:909767.CrossRefPubMedPubMedCentral
5.
Hwang BO, Park SY, Cho ES, Zhang X, Lee SK, Ahn HJ, Chun KS, Chung WY, Song NY. Platelet CLEC2-Podoplanin Axis as a Promising target for oral Cancer treatment. Front Immunol. 2021;12:807600.CrossRefPubMedPubMedCentral
6.
7.
Herzog BH, Fu J, Wilson SJ, Hess PR, Sen A, McDaniel JM, Pan Y, Sheng M, Yago T, Nieswarndt B, Morris AJ, Lupu F, Coughlin SR, McEver RP, Chen H, Kahn ML, L* X. Podoplanin maintains high endothelial venule integrity by interacting with platelet CLEC-2[J]. Nature. 2013;502(7469):105–9.CrossRefPubMedPubMedCentral
8.
Lowe KL, Finney BA, Deppermann C, Hgerling R, Gazit SL, Frampton J, Buckley C, Camerer E, Nieswandt B, Kiefer F, Watson SP. Podoplanin and CLEC-2 drive cerebrovascular patterning and integrity during development. Blood. 2015;125(24):3769–77.CrossRefPubMedPubMedCentral
9.
Takagi S, Sato S, Oh-hara T, Takami M, Koike S, Mishima Y, Hatake K, Fujita N. Platelets promote tumor growth and metastasis via direct interaction between Aggrus/podoplanin and CLEC-2. PLoS ONE. 2013;8(8):e73609.CrossRefPubMedPubMedCentral
10.
11.
Suzuki J, Aokage K, Neri S, Sakai T, Hashimoto H, Su Y, Yamazaki S, Nakamura H, Tane K, Miyoshi T, Sugano M, Kojima M, Fujii S, Kuwata T, Ochiai A, Tsuboi M, Ishii G. Relationship between podoplanin-expressing cancer-associated fibroblasts and the immune microenvironment of early lung squamous cell carcinoma. Lung Cancer. 2021;153:1–10.CrossRefPubMed
12.
Gülseren D, Gököz Ö, Karahan S, Karaduman A. Podoplanin expression in cutaneous squamous cell carcinomas and its relationship to histopathological prognostic factors. J Histotechnol. 2020;43(3):147–52.CrossRefPubMed
13.
Xu M, Wang X, Pan Y, Zhao X, Yan B, Ruan C, Xia L, Zhao Y. Blocking podoplanin suppresses growth and pulmonary metastasis of human malignant melanoma. BMC Cancer. 2019;19(1):599.CrossRefPubMedPubMedCentral
14.
15.
Suzuki H, Ohishi T, Kaneko MK, Kato Y. A humanized and defucosylated antibody against Podoplanin (humLpMab-23-f) exerts Antitumor activities in Human Lung Cancer and Glioblastoma Xenograft Models. Cancers (Basel). 2023;15(20):5080.CrossRefPubMed
16.
Mir Seyed Nazari P, Riedl J, Pabinger I, Ay C. The role of podoplanin in cancer-associated thrombosis. Thromb Res. 2018;164(Suppl 1):S34–9.CrossRefPubMed
17.
Suzuki-Inoue K, Tsukiji N, Shirai T, Osada M, Inoue O, Ozaki Y. Platelet CLEC-2: roles beyond hemostasis. Semin Thromb Hemost. 2018;44:126–34.CrossRefPubMed
18.
Suzuki-Inoue K. Platelets and cancer-associated thrombosis: focusing on the platelet activation receptor CLEC-2 and podoplanin. Blood. 2019;134:1912–8.CrossRefPubMed
19.
Finney BA, Schweighoffer E, Navarro-Núñez L, Bénézech C, Barone F, Hughes CE, Langan SA, Lowe KL, Pollitt AY, Mourao-Sa D, Sheardown S, Nash GB, Smithers N, Sousa C, Tybulewicz VL, Watson SP. CLEC-2 and Syk in the megakaryocytic/platelet lineage are essential for development. Blood. 2012;119(7):1747–56.CrossRefPubMedPubMedCentral
20.
Shirai T,O, Inoue,S Tamura N, Tsukiji T, Sasaki,H Endo,K Satoh M, Osada H, Sato-Uchida H, Fujii Y, Ozaki K, Suzuki-Inoue. C-type lectin-like receptor 2 promotes hematogenous tumor metastasis and prothrombotic state in tumor-bearing mice. J Thromb Haemost. 2017;15(3):513–25.CrossRefPubMed
21.
22.
Miyata K, Takemoto A, Okumura S, Nishio M, Fujita N. Podoplanin enhances lung cancer cell growth in vivo by inducing platelet aggregation. Sci Rep. 2017;7(1):4059.CrossRefPubMedPubMedCentral
23.
Wang X, Li W, Bi J, Wang J, Ni L, Shi Q, Meng Q. Association of high PDPN expression with pulmonary metastasis of osteosarcoma and patient prognosis. Oncol Lett. 2019;18(6):6323–30.PubMedPubMedCentral
24.
May F, Hagedorn I, Pleines I, Bender M, Vögtle T, Eble J, Elvers M, Nieswandt B. CLEC-2 is an essential platelet-activating receptor in hemostasis and thrombosis. Blood. 2009;114(16):3464–72.CrossRefPubMed
25.
Masahiko, Watanabe. Yoshikazu Sugimoto and Takashi Tsuruo. Expression of a Mr 41,000 glycoprotein Associated with Thrombin-independent platelet aggregation in high metastatic variants of murine B16 melanoma. Cancer Res. 1990;50:6657–62.
26.
Bambace NM, Holmes CE. The platelet contribution to cancer progression. J Thromb Haemost. 2011;9(2):237–49.CrossRefPubMed
27.
28.
Suzuki-Inoue K. Roles of the CLEC-2-podoplanin interaction in tumor progression. Platelets. 2018;4:1–7.
29.
Janowska-Wieczorek A, Wysoczynski M, Kijowski J, et al. Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int J Cancer. 2005;113:752–60.CrossRefPubMed
30.
Boucharaba A, Serre CM, Gres S, et al. Platelet derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest. 2004;114:1714–25.CrossRefPubMedPubMedCentral
31.
32.
Jain S, Zuka M, Liu J, Russell S, Dent J, Guerrero JA, Forsyth J, Maruszak B, Gartner TK, Felding-Habermann B, Ware J. Platelet glycoprotein ib alpha supports experimental lung metastasis. Proc Natl Acad Sci U S A. 2007;104(21):9024–8.CrossRefPubMedPubMedCentral
33.
Suzuki-Inoue K, Fuller GL, Garcia A, Eble JA, Pohlmann S, Inoue O, et al. A novel syk-dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2. Blood. 2006;107(2):542–9.CrossRefPubMed
34.
Hughes CE, Pollitt AY, Mori J, Eble JA, Tomlinson MG, Hartwig JH, O’Callaghan CA, Fütterer K, Watson SP. CLEC-2 activates syk through dimerization. Blood. 2010;115(14):2947–55.CrossRefPubMed
35.
Tone K, Stappers MHT, Willment JA, Brown GD. C-type lectin receptors of the Dectin-1 cluster: physiological roles and involvement in disease. Eur J Immunol. 2019 (12):2127–33.
36.
Lowe KL, Navarro-Nunez L, Watson SP. Platelet CLEC-2 and podoplanin in cancer metastasis. Thromb Res. 2012;129(Suppl 1):S30–37.CrossRefPubMed
37.
Martin EM, Zuidscherwoude M, Morán LA, Di Y, García A, Watson SP. The structure of CLEC-2: mechanisms of dimerization and higher-order clustering. Platelets. 2021;32(6):733–43.CrossRefPubMed
38.
Suzuki-Inoue K. Essential in vivo roles of the platelet activation receptor CLEC-2 in tumour metastasis, lymphangiogenesis and thrombus formation. J Biochem. 2011;150(2):127–32.CrossRefPubMed
39.
Hughes CE, Finney BA, Koentgen F, Lowe KL, Watson SP. The N-terminal SH2 domain of Syk is required for (hem)ITAM, but not integrin, signaling in mouse platelets. Blood. 2015;125(1):144–54.CrossRefPubMedPubMedCentral
40.
Metadata
Title
The podoplanin-CLEC-2 interaction promotes platelet-mediated melanoma pulmonary metastasis
Authors
Minjia Sheng
Ran Sun
Jianxin Fu
Gao Lu
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-12194-w

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue

Study Protocol

A randomised phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma (ARISTOCRAT): protocol for a multi-centre, double-blind, placebo-controlled trial

Research

Real-world advantage and challenge of post-autologous stem cell transplantation MRD negativity in high-risk patients with double-hit multiple myeloma

Research

Central venous access device terminologies, complications, and reason for removal in oncology: a scoping review

Retraction Note

Retraction Note: Swainsonine represses glioma cell proliferation, migration and invasion by reduction of miR-92a expression

Research

Understanding referral of patients with cancer in rural Ethiopia: a qualitative study

Systematic Review

Systematic literature review of real-world evidence for treatments in HR+/HER2- second-line LABC/mBC after first-line treatment with CDK4/6i
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits